Performance improvements from Asia Alternatives, Clarus, GGV
Venture portfolio’s focus on secondaries and funds of funds appears to pay off
Secondary funds strategy continues to bring results
CalSTRS sees gains from OrbiMed, Sofinnova, Shasta, GGV
Bregal abandons sale of pre-2008 vintage funds; Preqin survey shows investors unsatisfied with mounting fees paid on unallocated capital
CalSTRS sees gains from NEA, but a decline from ARCH
Money manager sees strong gains with IVP, Aisling, JP Morgan funds
SFERS sees broad gains in recent vintage funds; adds Battery, OrbiMed
Performance at IVP XII, Clarus Lifesciences II improves last year
Record distributions in 2013; the role of consultants; pension asset growth slows